{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:48:01Z","timestamp":1788871681909,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T00:00:00Z","timestamp":1419552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Stockholm County Council, Adolf H. Lundin Charitable Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Granulocyte transfusions are given to patients with life\u2010threatening infections, refractory to treatment. The donors are stimulated with corticosteroids\u2009\u00b1\u2009granulocyte colony stimulating factor (G\u2010CSF). However, data regarding the donors' safety is sparse. The objective was therefore to evaluate short\u2010 and long\u2010term adverse events (AE) in G\u2010CSF stimulated donors.\n                    <jats:bold>Study design and methods:<\/jats:bold>\n                    All consecutive granulocyte donors from 1994 to 2012 were identified through our registry. From the donation records, the number of aphereses, stimulation therapy, AE, blood values post donation, and recent status were evaluated.\n                    <jats:bold>Results:<\/jats:bold>\n                    One hundred fifty\u2010four volunteer donors were mobilized for 359 collections. Age at first granulocyte donation was 43 years (median; range 19\u201364 years). Follow\u2010up was 60 months (median; range 0\u2013229 months). The dose of G\u2010CSF per collection was 3.8 ug\/kg body weight (median; range 1.6\u20136.0 ug\/kg). Sedimentation agent was HES. Short\u2010term AE were mild. Blood values 4 weeks post donation with minor reductions\/elevations mostly resolved in later donations. Fourteen donors were excluded from the registry due to hypertension (4), diabetes (2), atrial flutter (1), breast carcinoma (1), urethral carcinoma in situ (1), MGUS (1), thrombosis (1), anaphylaxis (1), primary biliary cirrhosis (1), and unknown (1). Three donors are deceased due to diabetes, acute myocardial infarction, and unknown cause. All excluded\/deceased donors except one were excluded\/died at least 6 months after first granulocyte donation.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    No serious short\u2010term AE were observed. Due to the variability of diagnoses among excluded\/deceased donors, we propose that it is less likely that granulocyte donations have a causative impact on these donors' exclusion or death. J. Clin. Apheresis 30:265\u2013272, 2015. \u00a9 2014 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/jca.21373","type":"journal-article","created":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T10:07:32Z","timestamp":1419588452000},"page":"265-272","source":"Crossref","is-referenced-by-count":13,"title":["Eighteen years experience of granulocyte donations\u2014acceptable donor safety?"],"prefix":"10.1002","volume":"30","author":[{"given":"Ulla","family":"Axdorph Nygell","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital and Karolinska Institutet Stockholm Sweden"},{"name":"Department of Haematology Karolinska University Hospital and Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Soll\u00e9n\u2010Nilsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital and Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Lundahl","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital and Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,26]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"(3)CD005339","article-title":"Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction","author":"Stanworth SJ","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2010.01035.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2012.714906"},{"key":"e_1_2_7_5_1","first-page":"595\u2013597","volume-title":"Technical Manual","author":"Roback JD","year":"2008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1986.26386209383.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2866.2866"},{"key":"e_1_2_7_8_1","first-page":"CD005341","article-title":"Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction","author":"Massey E","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09190.x"},{"key":"e_1_2_7_10_1","article-title":"Granulocyte Transfusion Therapy","author":"Marfin A","journal-title":"J Intensive Care Med"},{"key":"e_1_2_7_11_1","unstructured":"NIH clinical trials.http:\/\/jic.sagepub.com\/content\/early\/2013\/08\/02\/0885066613498045. Last accessed April 16 2014."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01315.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01418.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03938.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2003.00373.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417667"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13668"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2012.10.003"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06312.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.003"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.173"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06524.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-218651"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01983.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.354"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920100408"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1981.21381201811.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-013-3156-9"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02948.x"},{"key":"e_1_2_7_30_1","first-page":"203","article-title":"Steroids: pharmacology, complications, and practice delivery issues","volume":"14","author":"Ericson\u2010Neilsen W","year":"2014","journal-title":"Ochsner J"},{"key":"e_1_2_7_31_1","unstructured":"The Swedish National Board of Health and Welfare's regulations regarding blood donation (SOSFS) 2009:28. Stockholm."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01997.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01425.x"},{"key":"e_1_2_7_34_1","unstructured":"Myocardial infarctions in Sweden 1988\u20132012. The National Board of Health and Welfare (Socialstyrelsen). Stockholm 2013. ISSN 1400\u20100511. ISBN 978\u201091\u20107555\u2010114\u20102."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029608320720"},{"key":"e_1_2_7_36_1","unstructured":"Cancer incidence in Sweden 2012. The National Board of Health and Welfare (Socialstyrelsen) Stockholm 2013. ISBN: 978\u201091\u20107555\u2010126\u20105."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2013.09.031"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.09.003"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01669.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01788.x"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21373","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:55:21Z","timestamp":1696348521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,26]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/jca.21373"],"URL":"https:\/\/doi.org\/10.1002\/jca.21373","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,26]]}}}